Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113477 · Präparat HOS-093937
Drugs by Therapeutic Area Interaction Recommendation concerning
Geometric mean change (%) co-administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine /Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Zidovudine/Abacavir Interaction not studied
Zidovudine/Lamivudine Lamivudine: AUC
Zidovudine 300 mg single dose Zidovudine : AUC
Lamivudine 150 mg single dose
Emtricitabine/Lamivudine Due to similarities, Kivexa
should not be administered
concomitantly with other
cytidine analogues, such as
emtricitabine.
ANTI-INFECTIVE PRODUCTS
Trimethoprim/sulfamethoxazole Interaction not studied. No Kivexa dosage adjustment
(Co-trimoxazole)/Abacavir necessary.
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40%
(Co-trimoxazole)/Lamivudine When concomitant
(160 mg/800 mg once daily for Trimethoprim: AUC administration with
5 days/300 mg single dose) Sulfamethoxazole: AUC co-trimoxazole is warranted,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3b23f2886f7d80d744304e64283fcb23c64e14afd5a52f5e8622a5373e4f7cc1 · Zeichen 1544–3217 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113478 · Präparat HOS-093937
7
patients should be monitored
(organic cation transporter clinically. High doses of
inhibition) trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided
ANTIMYCOBACTERIALS
Rifampicin/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations
through UGT induction.
Rifampicin/Lamivudine Interaction not studied.
ANTICONVULSANTS
Phenobarbital/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations
through UGT induction.
Phenobarbital/Lamivudine Interaction not studied.
Phenytoin/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations Monitor phenytoin
through UGT induction. concentrations.
Phenytoin/Lamivudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) phenobarbital (HOS-085617) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 387827645b1a19ba72bcdce583c6ff15cfaff9ba9910317f65a1827bc65c4f3b · Zeichen 3272–5207 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-116792 · Präparat HOS-094481
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Grapefruit or grapefruit juice May increase tacrolimus whole Avoid grapefruit or grapefruit
blood trough concentrations and juice.
increase the risk of serious adverse
reactions (e.g., neurotoxicity, QT
prolongation) [see section 4.4].
Ciclosporin May increase tacrolimus whole The simultaneous use of
blood trough concentrations. In ciclosporin and tacrolimus
addition, synergistic/additive should be avoided [see
nephrotoxic effects can occur. section 4.4].
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus
nephrotoxic or neurotoxic neurotoxic effects of tacrolimus. with drugs known to have
effects: nephrotoxic effects should be
aminoglycosides, gyrase avoided. When co-
inhibitors, vancomycin, administration cannot be
sulfamethoxazole + avoided, monitor renal
trimethoprim, NSAIDs, function and other side effects
ganciclovir, acyclovir, and adjust tacrolimus dose if
amphotericin B, ibuprofen, needed.
cidofovir, foscarnet
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ibuprofen (HOS-087884) amphotericin B (HOS-109312) trimethoprim (HOS-085184) cidofovir (HOS-110482) grapefruit juice (HOS-088787) vancomycin (HOS-110486) ganciclovir (HOS-085194) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage b0395308050c5d9d3dab6530a2530819d6fdce6a20dc173d21940107d84f6ae3 · Zeichen 1941–3853 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-116841 · Präparat HOS-094481
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing
hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or
spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is co-
administered with other agents that increase serum potassium, such as trimethoprim and cotrimoxazole
(trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like
amiloride. Close monitoring of serum potassium is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) amiloride (HOS-089052) triamterene (HOS-089051) trimethoprim (HOS-085184) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 30e6eeb2317cdee4b7657b83f2d6f0c944b78efdd91aa2523ea6b7ddcf01974a · Zeichen 16837–17392 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-118455 · Präparat HOS-094825
Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is
administered without CYP3A4 inhibitors. In vitro studies have shown that maraviroc does not
inhibit any of the major renal uptake transporters at clinically relevant concentrations (OAT1,
OAT3, OCT2, OCTN1, and OCTN2). Additionally, co-administration of maraviroc with tenofovir
(substrate for renal elimination) and cotrimoxazole (contains trimethoprim, a renal cation transport
inhibitor), showed no effect on the pharmacokinetics of maraviroc. In addition, co-administration
of maraviroc with lamivudine/zidovudine showed no effect of maraviroc on lamivudine (primarily
renally cleared) or zidovudine (non-P450 metabolism and renal clearance) pharmacokinetics.
Maraviroc inhibits P-glycoprotein in vitro (IC50 is 183 μM). However, maraviroc does not
significantly affect the pharmacokinetics of digoxin in vivo. It may not be excluded that maraviroc
can increase the exposure to the P-glycoprotein substrate dabigatran etexilate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) trimethoprim (HOS-085184) digoxin (HOS-086172) lamivudine (HOS-085829) zidovudine (HOS-085837) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 6e9f4ecd97f539896aacf725a92a940b796bdc8720e11860c99c90991dcb4097 · Zeichen 1398–2427 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-118467 · Präparat HOS-094825
Ritonavir AUC12: ↔ 0.93
Ritonavir Cmax: ↔ 1.02
Ritonavir C12: ↓ 0.74
Etravirine and Not studied. Based on the extent of
lopinavir/ritonavir, inhibition by lopinavir/ritonavir,
saquinavir/ritonavir or saquinavir/ritonavir or
atazanavir/ritonavir atazanavir/ritonavir in the absence of
etravirine, an increased exposure is
expected.
ANTIBIOTICS
Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg
Trimethoprim Maraviroc Cmax: ↔ 1.19 twice daily and
800 mg/160 mg BID Sulphamethoxazole/trimethoprim sulphamethoxazole/
(maraviroc 300 mg BID) concentrations not measured, no trimethoprim can be
effect expected. co-administered without
dose adjustment.
Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 be increased to 600 mg
Rifampicin concentrations not twice daily when
measured, no effect expected. co-administered with
rifampicin in the absence
of a potent CYP3A4
inhibitor. This dose
adjustment has not been
studied in HIV patients.
See also section 4.4.
Rifampicin + efavirenz Combination with two inducers has Concomitant use of
not been studied. There may be a risk CELSENTRI and
of suboptimal levels with risk of loss rifampicin + efavirenz is
of virologic response and resistance not recommended.
development.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) trimethoprim (HOS-085184) etravirine (HOS-088088) saquinavir (HOS-084522) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1af4c98082c3a7953761e56ffc31f5f4a9006530d26915e9825d9b7b7263f12b · Zeichen 14085–16301 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 34
HOS-118500 · Präparat HOS-094825
Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is
administered without CYP3A4 inhibitors. In vitro studies have shown that maraviroc does not
inhibit any of the major renal uptake transporters at clinically relevant concentrations (OAT1,
OAT3, OCT2, OCTN1, and OCTN2). Additionally, co-administration of maraviroc with tenofovir
(substrate for renal elimination) and cotrimoxazole (contains trimethoprim, a renal cation transport
inhibitor), showed no effect on the pharmacokinetics of maraviroc. In addition, co-administration
of maraviroc with lamivudine/zidovudine showed no effect of maraviroc on lamivudine (primarily
renally cleared) or zidovudine (non-P450 metabolism and renal clearance) pharmacokinetics.
Maraviroc inhibits P-glycoprotein in vitro (IC50 is 183 μM). However, maraviroc does not
significantly affect the pharmacokinetics of digoxin in vivo. It may not be excluded that maraviroc
can increase the exposure to the P-glycoprotein substrate dabigatran etexilate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) trimethoprim (HOS-085184) digoxin (HOS-086172) lamivudine (HOS-085829) zidovudine (HOS-085837) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 6e9f4ecd97f539896aacf725a92a940b796bdc8720e11860c99c90991dcb4097 · Zeichen 1454–2483 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 37–38
HOS-118508 · Präparat HOS-094825
Ritonavir AUC12: ↔ 0.93
Ritonavir Cmax: ↔ 1.02
Ritonavir C12: ↓ 0.74
Etravirine and Not studied. Based on the extent of
lopinavir/ritonavir, inhibition by lopinavir/ritonavir,
saquinavir/ritonavir or saquinavir/ritonavir or
atazanavir/ritonavir atazanavir/ritonavir in the absence of
etravirine, an increased exposure is
expected.
ANTIBIOTICS
37
Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg twice
Trimethoprim Maraviroc Cmax: ↔ 1.19 daily and sulphamethoxazole/
800 mg/160 mg BID Sulphamethoxazole/trimethoprim trimethoprim can be
(maraviroc 300 mg BID) concentrations not measured, no co-administered without dose
effect expected. adjustment.
Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 increased to 600 mg twice
Rifampicin concentrations not daily when co-administered
measured, no effect expected. with rifampicin in the absence
of a potent CYP3A4 inhibitor.
This dose adjustment has not
been studied in HIV patients.
See also section 4.4.
Rifampicin + efavirenz Combination with two inducers has Concomitant use of
not been studied. There may be a risk CELSENTRI and rifampicin
of suboptimal levels with risk of loss + efavirenz is not
of virologic response and resistance recommended.
development.
Rifabutin + PI Not studied. Rifabutin is considered CELSENTRI dose should be
to be a weaker inducer than decreased to 150 mg twice
rifampicin. When combining rifabutin daily when co-administered
with protease inhibitors that are with rifabutin and a PI
potent inhibitors of CYP3A4 a net (except tipranavir/ritonavir
inhibitory effect on maraviroc is where the dose should be 300
expected. mg twice daily). See also
section 4.4.
Concomitant use of
CELSENTRI and
fosamprenavir/ritonavir is not
recommended.
Clarithromycin, Not studied, but both are potent CELSENTRI dose should be
Telithromycin CYP3A4 inhibitors and would be decreased to 150 mg twice
expected to increase maraviroc daily when co-administered
concentrations. with clarithromycin and
telithromycin.
ANTICONVULSANTS
Carbamezepine, Not studied, but these are potent CELSENTRI dose should be
Phenobarbital, CYP3A4 inducers and would be increased to 600 mg twice
Phenytoin expected to decrease maraviroc daily when co-administered
concentrations. with carbamazepine,
phenobarbital or phenytoin in
the absence of a potent
CYP3A4 inhibitor.
ANTIFUNGALS
Ketoconazole 400 mg QD Maraviroc AUCtau: ↑ 5.00 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↑ 3.38 decreased to 150 mg twice
Ketoconazole concentrations not daily when co-administered
measured, no effect is expected. with ketoconazole.
Itraconazole Not studied. Itraconazole, is a potent CELSENTRI dose should be
CYP3A4 inhibitor and would be decreased to 150 mg twice
expected to increase the exposure of daily when co-administered
maraviroc. with itraconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) trimethoprim (HOS-085184) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) rifabutin (HOS-086262) etravirine (HOS-088088) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1b627b7cd1e4efc3a8fc8f7680c5fda5526614bbd2d1f72d7ed1fca6f8314992 · Zeichen 13851–18833 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-209321 · Präparat HOS-154301
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4218–4301 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-209396 · Präparat HOS-154301
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4217–4300 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-209466 · Präparat HOS-154315
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4218–4301 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-209535 · Präparat HOS-154315
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4218–4301 im Abschnitt
Wechselwirkungen · Kuvan
Kuvan 100 mg soluble tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-209696 · Präparat HOS-154361
Although concomitant administration of inhibitors of dihydrofolate reductase (e.g. methotrexate,
trimethoprim) has not been studied, such medicinal products may interfere with BH4 metabolism. Caution is
recommended when using such medicinal products while taking Kuvan.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-22T11:16:00Z · SHA-256 a25cb7ffeb557ba990802e7f4d8acae6157295a3e63763ca835e29013c04343a · Passage de341373eccbac4c67d42bc72c5fc73eadc96835267af360b88d0fb076bdf50a · Zeichen 0–269 im Abschnitt
Wechselwirkungen · Kuvan
Kuvan 100 mg powder for oral solution Kuvan 500 mg powder for oral solution · Abschnitt 4.5 · PDF-Seite 21
HOS-209720 · Präparat HOS-154361
Although concomitant administration of inhibitors of dihydrofolate reductase (e.g. methotrexate,
trimethoprim) has not been studied, such medicinal products may interfere with BH4 metabolism. Caution is
recommended when using such medicinal products while taking Kuvan.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-22T11:16:00Z · SHA-256 a25cb7ffeb557ba990802e7f4d8acae6157295a3e63763ca835e29013c04343a · Passage de341373eccbac4c67d42bc72c5fc73eadc96835267af360b88d0fb076bdf50a · Zeichen 0–269 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 14
HOS-209775 · Präparat HOS-154375
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing
hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or
spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is
co-administered with other agents that increase serum potassium, such as trimethoprim and
cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a
potassium-sparing diuretic like amiloride. Close monitoring of serum potassium is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) amiloride (HOS-089052) triamterene (HOS-089051) trimethoprim (HOS-085184) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage aac5d9318a66c91e23e4c1fc78590754f2d30cc155ff58f481f62c0b5cad0dff · Zeichen 17014–17568 im Abschnitt
Wechselwirkungen · Enyglid
Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-210666 · Präparat HOS-154563
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketoconazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) ketoconazole (HOS-084513) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-05T16:50:00Z · SHA-256 12b8cb591a06737df18eb1bbe30d3ed0dd1a0bc83bd3555d39ff6f7b72982ce3 · Passage 13edc1380f9089564cb6a15edbe32d520277583db26538ebfa53c278c01723d7 · Zeichen 1081–1504 im Abschnitt
Wechselwirkungen · Enyglid
Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-210671 · Präparat HOS-154563
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and
repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold
and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This lack
of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the safety
profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide
and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be
avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical
monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-05T16:50:00Z · SHA-256 12b8cb591a06737df18eb1bbe30d3ed0dd1a0bc83bd3555d39ff6f7b72982ce3 · Passage b3d5c7185030d7330d3356f73c3bf7ab48d2a6b40884d39bc9df8c7da53c6b16 · Zeichen 2021–2760 im Abschnitt
Wechselwirkungen · Repaglinide Krka
Repaglinide Krka 0.5 mg tablets Repaglinide Krka 1 mg tablets Repaglinide Krka 2 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-210701 · Präparat HOS-154571
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketoconazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) ketoconazole (HOS-084513) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-04T16:40:00Z · SHA-256 750cebf2c4f53148860d7f38c6b2067d5b0aa0233a26f1dad391b0ac23efb1ce · Passage 13edc1380f9089564cb6a15edbe32d520277583db26538ebfa53c278c01723d7 · Zeichen 1081–1504 im Abschnitt
Wechselwirkungen · Repaglinide Krka
Repaglinide Krka 0.5 mg tablets Repaglinide Krka 1 mg tablets Repaglinide Krka 2 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-210704 · Präparat HOS-154571
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and
repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold
and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This lack
of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the safety
profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide
and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be
avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical
monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-04T16:40:00Z · SHA-256 750cebf2c4f53148860d7f38c6b2067d5b0aa0233a26f1dad391b0ac23efb1ce · Passage b3d5c7185030d7330d3356f73c3bf7ab48d2a6b40884d39bc9df8c7da53c6b16 · Zeichen 2021–2760 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.